Evidence map›Paper›PMID 26783000›Full record

ReviewCurrent cardiology reports2016

Nuclear Imaging Guidance for Ablation of Ventricular Arrhythmias.

John Duell, Vasken Dilsizian, Mark Smith, Wengen Chen, Timm Dickfeld

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Review
  3. Article
  4. Metabolic Scar Assessment withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Article
  5. Cardiac radioablation in the treatment of ventricular tachycardia.Clinical and translational radiation oncology · 2021
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

John DuellMaryland Arrhythmia and Cardiology Imaging Group (MACIG), Baltimore, MD, USA.
Vasken DilsizianMaryland Arrhythmia and Cardiology Imaging Group (MACIG), Baltimore, MD, USA.
Mark SmithMaryland Arrhythmia and Cardiology Imaging Group (MACIG), Baltimore, MD, USA.
Wengen ChenMaryland Arrhythmia and Cardiology Imaging Group (MACIG), Baltimore, MD, USA.
Timm DickfeldMaryland Arrhythmia and Cardiology Imaging Group (MACIG), Baltimore, MD, USA. tdickfel@medicine.umaryland.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to an increase in the number of patients with heart failure and ventricular arrhythmias, ventricular tachycardia ablation has a growing clinical role. Long-term success rates remain suboptimal and require creating a detailed electroanatomic map during the procedure to identify fibrotic areas responsible for arrhythmias. Nuclear imaging can identify areas of abnormal myocardial perfusion, metabolism, and innervation, which all may enhance our ability to identify ablation targets, thus decreasing procedure time and improving success rates. Myocardial scar, as assessed by single-photon emission computed tomography (SPECT) perfusion imaging, has been shown to correlate with abnormal areas found during electroanatomic mapping. Abnormal metabolism as identified by (18)fluorodeoxyglucose-positron-emission tomography (PET) imaging has been shown to predict successful ablation sites and help correct errors made in the creation of the electroanatomic map. Abnormal cardiac sympathetic innervation can be identified using the purpose (123)I-meta-iodobenzylguanidine SPECT imaging, which may help in identifying triggers that initiate ventricular tachycardia and also predict successful ablation sites within an otherwise normal myocardium. In conclusion, these imaging modalities can not only offer new insights into the pathophysiology of ventricular arrhythmias but also have the potential to improve outcomes from ventricular tachycardia ablation procedures.

Indexed as

Catheter AblationPositron-Emission TomographyTomography, Emission-Computed, Single-PhotonFluorodeoxyglucose F18GuanidinesHeart FailureHumansIodine RadioisotopesPractice Guidelines as TopicPrognosisRadiopharmaceuticalsTachycardia, VentricularbenzylguanidineFluorodeoxyglucose F18GuanidinesIodine RadioisotopesRadiopharmaceuticalsCardiac mappingInnervationMetabolismNuclear imagingPerfusionVentricular tachycardia ablation

Identifiers

PMID26783000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.